Source: Stem Cell Therapeutics Corp
Posted: April 10, 2007 - 08:30 ET
Summary:
Stem Cell Therapeutics Corp. announced positive interim results from its currently enrolling Phase IIa- Safety Trial for NTxTM-265, the company's new stem cell stroke treatment. Results demonstrated the treatment could be safely administered to a population of patients with acute stroke.
